Published in Cancer Weekly, April 2nd, 2002
This publication reported phase-II results of 30 colorectal cancer patients given the I-131-labeled humanized CEA antibody. Two sets of patients were studied, 21 with measurable metastatic colorectal cancer, and 9 who had their metastases completely resected prior to therapy (adjuvant group). Both groups received a single dose of the product, whereas 5 patients with documented...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.